Mid-term safety profile evaluation of Bio-A absorbable synthetic mesh as cruroplasty reinforcement.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
11 2019
Historique:
received: 09 07 2018
accepted: 17 01 2019
pubmed: 25 1 2019
medline: 23 7 2020
entrez: 25 1 2019
Statut: ppublish

Résumé

The aim of the present paper is to report the results of a single institution series of hiatal hernia repair (HHR) with augmented mesh hiatoplasty focusing on safety and efficacy profile of Bio-A absorbable synthetic mesh. A retrospective evaluation of prospectively maintained database showed 120 consecutive patients submitted to HHR reinforced with bio-absorbable synthetic mesh. The study populations included two groups: (A) 92 obese patients-reinforced hiatoplasty concurrent with bariatric procedure; (B) 28 non-obese patients-reinforced hiatoplasty concurrent with antireflux surgery. Symptoms assessment was made with GERD-HRQL and Rome III. The X-ray with barium swallow, the CT scan, in selected cases, and the endoscopy were used as recurrence evaluation and as endoscopic complications assessment. Only patients with a mean follow-up of 12 months were included in this study. A Cox hazard was made to evaluate factors affecting the recurrence. No case of intra-peri and post-operative (mean follow-up of 41 months) complications mesh related were registered. The dysphagia-rate was 8.7% for Group A and 11% for Group B. 74% of Group A and 61% of Group B patients are actually PPIs free with median GERD-HRQL score of 4 (from 16) and 6 (from 23), respectively (difference pre-post-operative < 0.05). Recurrence rate was 5.4% in Group A and 7.1% in Group B. The Cox hazard analysis showed that the use of more than four stitches for cruroplasty represents a negative factor on recurrence (HR = 8; p < 0.05). This is, in our knowledge, the largest report (120 consecutive patients) with mid-term follow-up (41 months of mean FU) on bio-absorbable mesh on the hiatus in obese and non-obese patients. These results supports the use of absorbable mesh for HHR (safe profile-0% of complications rate), showing excellent recurrence rate results and good GERD symptoms control.

Identifiants

pubmed: 30675663
doi: 10.1007/s00464-019-06676-3
pii: 10.1007/s00464-019-06676-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3783-3789

Références

Int J Surg. 2014;12(8):794-7
pubmed: 24947948
Obes Surg. 2017 Oct;27(10):2768-2772
pubmed: 28808884
Rev Gastroenterol Disord. 2008 Fall;8(4):233-9
pubmed: 19107097
Surg Obes Relat Dis. 2014 Mar-Apr;10(2):250-5
pubmed: 24355324
Am J Gastroenterol. 2006 Nov;101(11):2619-28
pubmed: 16952280
J Gastrointest Surg. 2008 May;12(5):953-7
pubmed: 17882502
Surg Endosc. 2017 Dec;31(12):4913-4922
pubmed: 28523363
Surg Endosc. 2013 Dec;27(12):4409-28
pubmed: 24018762
J Gastrointestin Liver Dis. 2006 Sep;15(3):237-41
pubmed: 17013448
Surg Endosc. 2016 Jun;30(6):2374-81
pubmed: 26428202
Surg Obes Relat Dis. 2013 May-Jun;9(3):356-61
pubmed: 22867558
Ann Otol Rhinol Laryngol. 2013 Nov;122(11):717-24
pubmed: 24358633
Surg Laparosc Endosc Percutan Tech. 2012 Dec;22(6):498-502
pubmed: 23238375
JSLS. 2012 Jan-Mar;16(1):55-9
pubmed: 22906331
Surg Obes Relat Dis. 2013 Mar-Apr;9(2):159-91
pubmed: 23537696
Obes Surg. 2013 Dec;23(12):1981-6
pubmed: 23754240
J Pediatr Surg. 2007 Jan;42(1):252-6
pubmed: 17208576
Hernia. 2017 Aug;21(4):623-628
pubmed: 28396955
J Gastrointest Surg. 1998 Mar-Apr;2(2):141-5
pubmed: 9834409
Ann Surg. 2016 Feb;263(2):258-66
pubmed: 26445468
Obes Surg. 2015 Jan;25(1):159-66
pubmed: 25348434
Am J Surg. 2016 Jan;211(1):226-38
pubmed: 26520872
Surg Endosc. 2018 Jul;32(7):3295-3302
pubmed: 29340811
Hernia. 2013 Feb;17(1):81-4
pubmed: 22581201
Minim Invasive Ther Allied Technol. 2014 Oct;23(5):302-8
pubmed: 24773371

Auteurs

Angelo Iossa (A)

Division of General Surgery and Bariatric Centre of Excellence, Department of Medical-Surgical Sciences and Biotechnologies, University of Rome "La Sapienza", Rome, Italy. angelo.iossa@gmail.com.

Gianfranco Silecchia (G)

Division of General Surgery and Bariatric Centre of Excellence, Department of Medical-Surgical Sciences and Biotechnologies, University of Rome "La Sapienza", Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH